“Oral steroids helped reduce the risk of major kidney outcomes for patients with immunoglobulin A (IgA) nephropathy, the TESTING study found.
In a randomized trial of 503 participants, those who received oral methylprednisolone saw a 47% risk reduction for a composite kidney outcome — defined as a 40% eGFR decline or kidney failure resulting in dialysis, transplantation, or kidney disease-related death — meeting the primary endpoint (event rate 7.0 vs 11.8/100 patient-years; HR 0.53, 95% CI 0.39-0.72, P<0.0001), reported Vlado Perkovic, MBBS, PhD, of the University of New South Wales in Sydney.”
Learn more here.